High volatility in Beam Therapeutics Inc. stock price on Friday which ended trading at $72.60 (Updated on March 05, 2021) Sell candidate since 2021-02-23 Loss -24.75% PDF . Beam Therapeutics' new approach offers more precision than CRISPR. BEAM, Beam Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Get the latest Beam Therapeutics Inc. BEAM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Broadly, biotech stocks were under pressure. Beam Therapeutics General Information Description. © 2021 SwingTradeBot. Robinhood Proxies – The Private and Public Markets Can Be Very Connected. All rights reserved. If analysts are even close to being on target, it may be time for early investors to cash in on their shares of Beam Therapeutics Inc. (NASDAQ:BEAM). Beam Therapeutics Inc. (NASDAQ: BEAM) is -12.69% lower on its value in year-to-date trading and has touched a low of $13.00 and a high of $126.90 in the current 52-week trading range. Beam Therapeutics, a company focused on genome editing, is in a strange situation. Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. According to 6 analysts, the average rating for BEAM stock is "Buy." X Guide makes molecular "vehicles" to deliver genetic medicines. Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. Get the latest Beam Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Beam Therapeutics investment advice, charts, stats and more. Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. A high-level overview of Beam Therapeutics Inc. (BEAM) stock. The stock of the Cambridge, Massachusetts-... Beam Therapeutics was co-founded by David Liu, who invented base editing and prime editing technologies for gene editing. This is a 25.60% increase since the beginning of the trading day. Find out if BEAM (XNAS) is the best investment for you. Mobile App. Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. BEAM Stock Analysis Overview What this means: Beam Therapeutics Inc (BEAM) gets an Overall Rank of 59, which is an above average rank under InvestorsObserver's stock ranking system. 6 Wall Street analysts have issued ratings and price targets for Beam Therapeutics in the last 12 months. The post 7 CRISPR Stocks for the Future of Medicine appeared f... CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ... Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately. It has a research and clinical collab... [Read more...]. Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs Successful Initial Public Offering Completed and Continued Advancement ... CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today annou... Beam Therapeutics Inc. (NASDAQ: BEAM) is not exactly a household name in corporate America. We will alert you to important technical developments on your Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. Beam Therapeutics Presents First Data Highlighting Base Editing Program For Glycogen Storage Disease Type Ia At AASLD (Nov 13 Reuters). Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Beam Therapeutics Inc. Common Stock (BEAM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Beam Therapeutics is selling for 92.30 as of the 5th of March 2021. Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. Tech Stock Indices: Do Bulls Have A Problem? Listen in to hear how you can profit in 2021 and beyond. Description: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. You may wish to incorporate that into your trading strategies. Beam Therapeutics develops and commercializes DNA base editing technologies for the treatment of human disease.